Skip to main content

Closed

URGN: UroGen Pharma Ltd. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+9.3% / yr

Operating margin-77.0%

ROIC-50.9%

Financially safe

Stretched

Debt / equity-1.59×

Interest coverage-2.8×

Current ratio4.69×

UroGen Pharma Ltd.

URGNNASDAQ·USD·Closed

UroGen Pharma Ltd.

URGNNASDAQ·USD·Closed

$38.24

−6.94%

$38.24

−$2.85 (6.94%)

52W Range

80thpctl

Volume

1.04×avg

Mkt Cap

1.86BUSD

P/E

-13.9TTM

Div Yield

–ann

52W Range

80thpctl

Volume

1.04×avg

Market Cap

1.86BUSD

P/E Ratio

-13.9TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings